Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Three months now since their "Interviewing" for a Primary Investigator at ASCO. Three months since their feature presentation at Marcum MicroCap. Lets see.
No new investors unless you count the .02 give away.
No Primary Investigator
No Clinical Trial locations
No IND
No Pre-Ind
But what the hell KW only makes $16,250 a month and its all TD2's fault anyway right? Oh and again what exactly does Crabtree do for $169,000 a year?
Qtr. ended 7/31/16.
I expect the 10-Q will be released today after market closes Friday afternoon is a great time to dump bad news.
Another Month almost gone and still no Principle Investigator. No pre-ind submission. No clinical trial funding information. I think December is a pipe dream.
I'm not saying that it will be Phase One but it is certainly a possibility everyone needs to consider.
There are two words that could be spoken by the FDA that would destroy whats left of this companies ability to go on. Phase One
Here is a link to the process
https://secure.emmes.com/pactweb/system/files/cber101032204jf.pdf
Actually they do schedule the pre-ind. PMCB will submit a request the FDA will reply within 14 days with a date up to 60 days from the time of request. Meeting package must be submitted 4
weeks prior to meeting, includes:
Pre-clinical data
Product manufacturing scheme
Data regarding product
characterization/proposed specifications
Proposed clinical protocol
Specific questions grouped by discipline
(product, pre-clinical, clinical)
No i don't think some understand that every share traded is bought and sold.
We finally agree on something.
If that's what you want to believe but how do you explain the fact that just as many people were posting neg comments when they were not a bio tech company. And honestly i think half of the people that post here go back to the efood days. If a big bio wanted the technology they would have no problem just paying for it. Conspiracy theories are only useful for those that have no facts.
First of all penny stocks are where you usually have the most conversation on message boards and second does anyone with any sense of reality really believe that PMCB is feared in the marketplace. The biotech marketplace where companies are willing to spend billions and billions on M+A for any treatments with potential.
Its "slated" ? By who ? They have not even requested a pre-ind yet. After a pre-ind that takes up to 60 days they have to answer any of the questions the FDA sends them or fix anything that they submitted that the FDA doesn't like. That could take an hour or 60 months depending on what it is. And there will be something the FDA asks them to correct or explain there always is.
So 1/1/17 Kenny will have been here 3 years. He has a product that already had two clinical trials with data. The team that conducted those trials on board and here we sit 300,000,0000 + shares sold later and still no pre-ind no principal inv. very little money on hand and no institutional investors. WOW what a below average performance. Half or more of your accomplishments have nothing to do with KW
The year KW took over (2013) there were 482,000,000 shares now there are at least 848,000,000 and by years end probably 900,000,000 and still no money to fund trials. Almost double the amount of shares and what has he accomplished? A couple of mouse studies that shareholders can't see the results from. And a rat with no immune system that has healthy blood sugar.
What manipulation are you talking about? What has this company done to warrant a stock price any higher then this? I would say a 35 million $ market cap for a company that has done nothing but sell shares and issue PR's for the last 4 years is fairly high.
Posted 10/24 when the PPS was .25. I have read this same BS hundreds of times here and on yahoo how you better get in now at these cheap prices from when it was in the .30's all the way down here. And now PMCB is selling millions and millions of shares at .02 and people think this is a good thing. KW deserves a raise?? The guy is selling shares at .02 to pay for his raise. This company will be at a billion plus shares by the end of 2016 and the stock will be under .01 and i will still be reading about what a gift it is to be able to buy shares this cheap. LOL unreal.
Posting articles from a year ago only shows how inept the management of this company is. Still no principal investigator. No pre-ind meeting and no ATM available. Selling shares at .02 tells me that there is no big pharma interest.
Your welcome Anytime I can add clarity to rampant speculation.
Yes I know but they don't work it out with TD2 they send them a date and that's it. They don't negotiate the date its a letter stating this is your pre-ind date and time be there.
Actually the FDA schedules the meeting not TD2 i know many would like to believe that somehow PMCB will get special treatment from the FDA but believe me they won't. The FDA doesn't care who you are or who your associated with. They give everyone big and small the same treatment. They don't kiss anyone's ass.
Really. Thanks for that info but i knew that already and i also know it takes up to 60 days to get a pre-ind scheduled from the time you apply and then after you have made any changes the FDA asks for (And there will be changes) and you can apply for IND its 30 days from the time the FDA receives that. Q4 trials?? I don't think so and i think they already know that.
Pete just so you understand. NDA's don't happen until after all clinical trials are complete they are not filed with IND's.
Another week and still no Primary Investigator no Pre-Ind meeting scheduled. I expect Kenny esq. will wait until his next prerecorded CC in Oct. to tell us all that he is working really really hard and that he still has hundreds of i's to dot and t's to cross and don't worry the clinical trial will start in 2017 he promises.
They only have to sell 643,650 shares a year @.02 to pay the rent. With the amount out there already that's like change you find in your couch cushions.
They have answered. Its called silence because there is nothing to report.
If this is as obvious as some claim why isn't BUYINS doing anything about it. Maybe its because it is not happening and never has been. Its just another myth that the long time holders of this stock have been spreading for over a decade.
SILVER SPRING, Md., Oct. 01, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box ®, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech after releasing the latest short sale data through September 29, 2015. BUYINS.NET will monitor the market makers of PharmaCyte Biotech’s stock daily for compliance with fair market-making requirements.
Seems to me they only care about the people they are selling to next and not the ones that have been holding and waiting for years and years.
A CEO's job is vision and planning not see and react.
Kenny esq is selling shares at .02 and this is good business how? Most of you paid 5-10 times that amount for your shares. Where was the forward thinking when it came to raising capital when the share price was .10-.15 and the ATM was available. What was his "protecting shareholder value" statement all about? Any CEO that cannot look further then day by day is not a good CEO.
Thinking "outside the box"?? Any competent CEO would have raised capital long before it got to the point of having to almost give away shares.
I guess the lesson in running a small business is wait until your market cap drops below 75 million so you can't use your ATM and then flood the market with .02 shares while your loyal investors get the shaft. Great lesson maybe KW will teach business at Harvard when he retires.
Don't remember asking for help. I am offering my opinion just like you, I am waiting. Have been waiting and unless that pre-ind happens soon we can kiss December goodbye.
Ryan and Gruden were snake oil salesman and Ryan didn't want KW and Gruden wanted her $3 million in free shares and 5k a month to retire. And we shall see what KW does he hasn't proven anything to me or the investment community yet.
Who cares about Dr Ryan. He was as crooked as Pat Gruden and BTW they hired Crabtree and she hired KW so ....
Oh ya its right there in the 10k under put options. Oh wait no there not it just says they issued 67,000,000 shares and received 1.3 million $$. Either way its another great example of a CEO destroying shareholder value when he should have been using the ATM selling 10,000,000 shares at .10 when he could have.
Sure whatever you say. Someone bought warrants at .02 and agreed only to sell when they hit the .03's sounds logical. LOL
Those are not warrants it was a stock sale.
The "funding" company is exercising their warrants at .12 so they can sell at .03 that makes a lot of sense. LOL
Sure it has. Someone with bad eyesight.
Warrants
The warrants issued by the Company are classified as equity. The fair value of the warrants was recorded as additional-paid-in-capital, and no further adjustments are made.
For stock warrants paid in consideration of services rendered by non-employees, the Company recognizes consulting expense in accordance with the requirements of ASC 505-50 and ASC 505, as amended.
On January 21, 2014, the Company began the implementation of its “Warrant Conversion Program.” The program consists of offering every holder of Class A warrants the ability to exercise their Class A warrants, with an exercise price of $0.075 per share, into shares of common stock and an equal number of new Class D warrants, with an exercise price of $0.25 per warrant share. As of April 30, 2016, 18,755,200 Class A warrants had been converted for total cash proceeds of $1,380,720 and conversion of $25,920 of debt to an officer. The Company has also begun to offer holders of its Class B warrants, with a conversion price of $0.12 per share, with the same terms. As of April 30, 2016, 2,318,000 Class B warrants had been exercised for total cash proceeds of $278,160. An aggregate of 18,755,200 Class D Warrants have been issued in connection with this program.
On September 1, 2014 the Company granted 854,308 Class D Warrants to purchase common stock as part of the Warrant Conversion Program. This resulted in an expense of $100,000 under a consulting agreement to facilitate the Warrant Conversion Program. This expense is included in general and administrative expense in the consolidated statements of operations.
F-20
On March 23, 2015, the Company granted 10,000,000 cashless warrants to acquire stock at an exercise price of $0.11 per share, which expire on March 23, 2020. These warrants were accounted for using the equity method and resulted in a non-cash expense of $791,506 and $122,764 for the years ended April 30, 2016 and 2015, respectively.
On March 23, 2015, the Company granted 5,000,000 warrants to acquire stock at an exercise price of $0.11 per share. The warrants expired on December 31, 2015 without the warrants being exercised. These warrants were accounted for using the equity method and resulted in a non-cash expense of $113,834 and $17,656 for the years ended April 30, 2016 and 2015, respectively.
On December 31, 2015, warrants to purchase 5,000,000 shares of unregistered common stock of the Company expired. The warrant agreement was dated March 23, 2015 and the terms stated the exercise price of warrants was $0.11 per share.
On January 7, 2016, the Company entered into Stock and Warrant Purchase Agreements with two investors and closed a private placement to them. Pursuant to the Stock and Warrant Purchase Agreements, the Company sold to the investors, in equal amounts, an aggregate of 17,000,000 shares of its unregistered common stock, and also sold to the investors, in equal amounts, unregistered warrants to purchase an additional total of 17,000,000 shares of its unregistered common stock, for $1,020,000 in aggregate gross proceeds. The terms of the Stock and Warrant Purchase Agreements for these warrants state the exercise price is $0.12 per share and the expiration date of these warrants is January 7, 2021. Using the Black Scholes warrant pricing model, the Company determined the aggregate value of these warrants to be approximately $967,000. These warrants have a cashless exercise feature.